2127107-15-5
Chemical Structure
Lasmotinib
Synonym(s): PHI-101
- CAS No.: 2127107-15-5
- Formula:C19H19FN4O2S
- Molecular Weight:386.44
InChIKey: ULVAGWVTXBTFRN-AWEZNQCLSA-N
SMILES: NC(NC1=C(SC(C#CC2=CC(F)=CC=C2)=C1)C(N[C@H]3CCCNC3)=O)=O
Biological Activity: Lasmotinib (PHI-101) is a FLT3 and CHK2 inhibitor. Lasmotinib potently inhibits FLT3 single activating mutations (ITD or TKD mutants) and has inhibitory activity against FLT3 double (ITD/D835Y or ITD/F691L) and triple (ITD/D835Y/F691L) resistance mutations. Lasmotinib synergizes with Venetoclax (HY-15531) or Azacytidine to inhibit leukemia. Lasmotinib exhibits anticancer activity against ovarian and breast cancer[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lasmotinib | 98.16% | Lasmotinib (PHI-101) is a FLT3 and CHK2 inhibitor. Lasmotinib potently inhibits FLT3 single activating mutations (ITD or TKD mutants) and has inhibitory activity against FLT3 double (ITD/D835Y or ITD/F691L) and triple (ITD/D835Y/F691L) resistance mutations. Lasmotinib synergizes with Venetoclax (HY-15531) or Azacytidine to inhibit leukemia. Lasmotinib exhibits anticancer activity against ovarian and breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Nam K Y, et al. PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia[J]. Blood, 2020, 136: 28.
- [2]. Sung G J, Kim K A, Nam K Y, et al. Evaluation of Synergistic Anti-Leukemic Efficacy of PHI-101 in Preclinical Model of FLT3-ITD Acute Myeloid Leukemia. Blood, 2023, 142: 5949.
- [3]. Han J H J, Kim K T, Im J, et al. PHI-101, a potent and novel inhibitor of CHK2 in ovarian and breast cancer cells. Cancer Research, 2021, 81(13_Supplement): 1461-1461.
- [4]. Hwang H, Sung G J, Kim K A, et al. PHI-101 synergizes with chemotherapy and venetoclax in preclinical models of acute myeloid leukemia. Cancer Research, 2024, 84(6_Supplement): 7153-7153.
Keywords
